Rigel Pharmaceuticals (RIGL) has cleared the final regulatory hurdle to secure the global rights for the breast cancer drug Veppanu, cutting a $70M upfront check to partners Arvinas (ARVN) and Pfizer ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the appointment of Alison L. Hannah, M.D. to the role ...
(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...
Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.
Rigel Pharmaceuticals’ RIGL first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the ...
NEW YORK (AP) -- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped ...
On Feb. 18, 2021, Eli Lilly coughed up $125 million upfront to license R552 from Rigel Pharmaceuticals. This is a small molecule drug designed to inhibit RIPK1, a protein that regulates which cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results